Gerresheimer has agreed to sell its lab glassware business to a private equity investor, describing the deal as part of an effort to focus on delivery devices and pharmaceutical packaging.
Aluminium adjuvants should not be used in trial placebos according to UK scientists who say the differing physical and biological properties of alum salt forms makes some safer than others.
PharmaJet has inked a multi-year deal with the World Health Organization for its needle-free technology, which uses 80% less vaccine than traditional methods.
Catalent has more than doubled its biologics business since it went public in 2014, but the sector still represents less than 5% of the CDMO’s revenues.
A device that isolates and sprays a patient’s own stem cells onto serious burns could have significant implications in the organ regeneration industry, says developer RenovaCare.
Grunenthal has reiterated the benefits of its anti-crush intac tech after licensee Endo withdrew its request to have Opana ER labelled as “abuse deterrent."
Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.
Drug manufacturers that change hard gelatin capsule suppliers do not need to seek approval beforehand under a policy introduced by the US FDA this week.
Phages, peptides and live biotherapeutics could help combat antibiotic-resistant bacteria but don’t expect heavy R&D investment until people start dying from post-operative infection, says EpiBiome.
Alnylam’s RNAi manufacturing plant will be operational by 2018 and the firm says it is willing to invest in a second facility depending on its pipeline success.
Acino has agreed to sell its transdermal delivery patch business Luye Pharma Group in a deal that will include its manufacturing site in Miesbach, Germany.
Regulatory approvals are driving interest in West's Smartdose and Crystal Zenith delivery technologies, the firm says ahead of the launch of a monthly-dose version of Amgen's Repatha.
Researchers suggest targeted nanosystem drug delivery could be the key to crossing gastrointestinal tract and blood-brain barriers – a prevailing issue with oral medications.
Japan's Astellas has agreed to carry out clinical trials of a vaccine for serious diarrhoeal diseases which does not need to be refrigerated or injected and is produced in transgenic rice plants.
A transdermal patch formulation of the most commonly used Alzheimer's disease (AD) drug could be on the market in 2019 - two to three years earlier than expected.
Researchers have developed a new magnetically controlled drug that can dissolve clots up to 4,000 times more efficiently than ordinary enzyme-based drugs.
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the next year – with several implications for pharma back on Earth.
Cobra Biologics has teamed up with Touchlight to test an AAV vector production platform they claim will make manufacturing gene therapies for trials cheaper and faster.
The US FDA has approved Probuphine, a subdermal buprenorphine treatment for opioid dependence using Titan Pharmaceuticals’ ProNeura drug delivery platform.
Roche’s subcutaneous formulation of MabThera is about reducing the treatment burden for patients and not protecting it from impending biosimilar competition, the firm says.
Combination therapies and collaboration will be key in curing cancer, according to Pfizer which has seen 'astounding progress' in its immuno-oncology partnership with Merck KGaA.
As “one of the fastest growing areas in pharma,” the demand for finished dosage formulations is having an impact on several aspects of the CMO industries.
Rumoured IPO-ready Capsugel has added micro-dose capabilities at its facility in Ploërmel, France citing its acquisition of Xcelience as the driver for the expansion.
Full production at Catalent’s Beinheim softgel plant has begun five months after the discovery of out-of-place capsules led to French regulators suspending operations.
GSK has confirmed its new UK plant will continue to supply the US with Ellipta inhalers after capacity at its facility in North Carolina comes online this year.
